Journal profile · Pharmacology & Pharmacy
Anti-Cancer Drugs
ISSN 0959-4973 · eISSN 1473-5741 · Lippincott Williams and Wilkins Ltd. · UNITED STATES · Monthly · Founded 1990
Anti-Cancer Drugs: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.02; JCR Q3 (journal website); hybrid open access; review 4–8 weeks (community reports); community-reported acceptance: easy; 120 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Anti-Cancer Drugs is published by Lippincott Williams and Wilkins Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer therapeutics and mechanisms, Cancer Treatment and Pharmacology and Colorectal Cancer Treatments and Studies, together about 28.5% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.
Source: LetPub
Research area (LetPub): Pharmacology & Pharmacy
Editor-in-chief Sergio HuertaPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer therapeutics and mechanismsBiochemistry, Genetics and Molecular Biology10.3%
- Cancer Treatment and PharmacologyMedicine10.2%
- Colorectal Cancer Treatments and StudiesMedicine8.1%
- Lung Cancer Treatments and MutationsMedicine7.6%
- Lung Cancer Research StudiesMedicine6.2%
- Drug Transport and Resistance MechanismsMedicine4.6%
- HER2/EGFR in Cancer ResearchMedicine3.9%
- Cancer-related Molecular PathwaysMedicine3.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q4 · ONCOLOGY · rank 250/333
- JCR Q3 · PHARMACOLOGY & PHARMACY · rank 249/356
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.02LetPub ·
- Impact factor (publisher)
- 2Publisher website ·
- CiteScore 2026-06
- 4.6LetPub ·
- SJR 2026-06
- 0.51LetPub ·
- SNIP 2026-06
- 0.42LetPub ·
- h-index
- 88LetPub ·
- h-index
- 115OpenAlex ·
- i10-index
- 2,789OpenAlex ·
- 2-year mean citedness
- 2.2OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 27.32%LetPub ·
Volume
- Articles per year
- 103LetPub ·
Articles by year OpenAlex count · 5,049 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 43 | 11 | 13 |
| 2025 | 120 | 39 | 212 |
| 2024 | 106 | 26 | 367 |
| 2023 | 85 | 26 | 470 |
| 2022 | 206 | 46 | 1,603 |
| 2021 | 239 | 46 | 2,388 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref
Not usableThis publisher's "received" date is mostly when the revised manuscript arrived (78% of articles were "accepted" within 3 days), so it cannot measure review time
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- EasyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Lippincott Williams and Wilkins Ltd.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1990
- ISSN
- 0959-4973
- Electronic ISSN
- 1473-5741
- Latest issue on the website
- Volume 37, Issue 8 (September 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
FAQ
Frequently asked questions about Anti-Cancer Drugs
What CAS zone is Anti-Cancer Drugs in?
In the 2025 upgraded edition of the CAS Journal Ranking, Anti-Cancer Drugs is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology / Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Anti-Cancer Drugs?
The latest impact factor listed by LetPub is 2.02; CiteScore 4.6, h-index 115.
How long does peer review take at Anti-Cancer Drugs?
Authors report an average review time of 4–8 weeks; the community-reported acceptance is “Easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Anti-Cancer Drugs in?
The journal's website gives JCR Q3; by category, ONCOLOGY Q4 (250/333), PHARMACOLOGY & PHARMACY Q3 (249/356). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 4 of Medicine.
Which databases index Anti-Cancer Drugs?
According to LetPub and DOAJ records, Anti-Cancer Drugs is indexed in SCIE and Scopus.
Is Anti-Cancer Drugs open access, and what is the APC?
Anti-Cancer Drugs is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .